Clinical Trials Browser

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Myeloid, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT01976741 2021-05-06

Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)

Phase 1 Completed

168 enrolled 59 charts

GenitourinaryHead & NeckThoracic

Adenocarcinoma of Lung, Urinary Bladder Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms

NCT00509821 2019-04-05

Enzastaurin Before and Concomitant With Radiation, Followed by Enzastaurin in Participants With Newly Diagnosed Glioblastoma

Phase 2 Completed

60 enrolled 11 charts

CNS

Glioblastoma

NCT01433731 2016-03-24

Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)

Phase 1 Completed

18 enrolled 7 charts

DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous

Clinical Trials

Asciminib Treatment Optimization in ≥ 3rd Line CML-CP

POLAR

Phase 1/2 Study of BBT-176 in Advanced NSCLC With Progression After EGFR TKI Treatment

First in Human Study of M4344 in Participants With Advanced Solid Tumors

OPTIC-2L

Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)

Enzastaurin Before and Concomitant With Radiation, Followed by Enzastaurin in Participants With Newly Diagnosed Glioblastoma

Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)